Product Information
CLIND PH-BENZOYL PERO 1.2-2.5% is a generic product labeled by Actavis Pharma, Inc., priced at $0.7668 per GM under NDC 00591391668. Its NADAC has been published 350 times since Oct 23, 2019.
FDA first approved this application on Jun 19, 2015.
Strength
25; 10 mg/g; mg/g
Manufacturer
Actavis Pharma, Inc.NDC
00591391668
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
6/17/2026
Active Ingredients
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATEApproval Type
Generic (ANDA)
FDA Application
ANDA205128FDA Approved
6/19/2015
On Market Since
2/19/2019
Pharmacological Classes
Price Statistics
The NADAC for CLIND PH-BENZOYL PERO 1.2-2.5% has been published 350 times since Oct 23, 2019, and over the history we have for it it has declined 89.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7668 per GM |
|---|---|
| All-time high | $7.4004 (Mar 11, 2020) |
| All-time low | $0.7668 (Jun 17, 2026) |
| 52-week high | $0.9869 |
| 52-week low | $0.7668 |
| Median price | $1.3083 |
| Average price | $1.7195 |
| Largest weekly change | +71.0% (Feb 22, 2023) |
| Weeks tracked | 350 |
| Tracking since | Oct 23, 2019 |
1W
N/A
1M
N/A
3M
N/A
6M
-5.7%
1Y
-22.3%
3Y
-46.6%
5Y
-57.8%
All
-89.6%
Last surveyed Jul 1, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Clindamycin phosphate and benzoyl peroxide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clindamycin phosphate and benzoyl peroxide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Lincosamide Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLIND PH-BENZOYL PERO 1.2-2.5%?
The current National Average Drug Acquisition Cost (NADAC) for CLIND PH-BENZOYL PERO 1.2-2.5%, manufactured by Actavis Pharma, Inc., is $0.7668 per GM (NDC 00591391668), effective Jul 1, 2026.
How has the price of CLIND PH-BENZOYL PERO 1.2-2.5% changed over time?
Over the history we have for it, the NADAC for CLIND PH-BENZOYL PERO 1.2-2.5% has declined 89.6%. It has been tracked across 350 weekly CMS publications since Oct 23, 2019.
What are the highest and lowest recorded NADAC prices for CLIND PH-BENZOYL PERO 1.2-2.5%?
Since Oct 23, 2019, the NADAC for CLIND PH-BENZOYL PERO 1.2-2.5% has ranged from a low of $0.7668 (Jun 17, 2026) to a high of $7.4004 (Mar 11, 2020), with a median of $1.3083 per GM.
Are there cheaper alternatives to CLIND PH-BENZOYL PERO 1.2-2.5%?
No other NADAC-published product currently shares the active ingredient and strength of CLIND PH-BENZOYL PERO 1.2-2.5% in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLIND PH-BENZOYL PERO 1.2-2.5%?
CLIND PH-BENZOYL PERO 1.2-2.5% (NDC 00591391668) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.